Soligenix (SNGX) Q3 2024 earnings summary

Executive summary

• Focused on developing and commercializing products for rare diseases, with two segments: Specialized BioTherapeutics and Public Health Solutions.

• Key pipeline includes HyBryte™ for cutaneous T-cell lymphoma (CTCL), SGX302 for psoriasis, SGX945 for Behçet's disease, and dusquetide-based therapies for inflammatory diseases.

• HyBryte™ is advancing to a second Phase 3 trial, with enrollment targeted by end of 2024 and top-line results in 2026; Phase 2 SGX945 in Behçet's disease and SGX302 in psoriasis data expected in first half of 2025.

• Strategic initiatives include patent grants in Europe and Hong Kong for synthetic hypericin production and a partnership with Sterling Pharma Solutions to scale manufacturing.

• Public Health Solutions segment includes vaccine candidates for ricin, filoviruses, and COVID-19, supported by government grants.

Financial highlights

• Net loss for Q3 2024 was $1.72 million, up 3% year-over-year; nine-month net loss was $5.28 million, up 22% year-over-year.

• Revenues for Q3 2024 were $0, down from $130,440 in Q3 2023; nine-month revenues were $119,371, down 80% year-over-year.

• Cash and cash equivalents as of September 30, 2024, were $9.84 million, up from $8.45 million at year-end 2023.

• Research and development expenses for nine months were $2.56 million, up 1% year-over-year; Q3 R&D was $1.0 million, up from $0.8 million.

• General and administrative expenses for nine months were $3.16 million, up 2% year-over-year; Q3 G&A was $0.9 million, down from $1.0 million.

Outlook and guidance

• Management believes resources are sufficient to support operations through Q2 2025, but not for 12 months beyond the financial statement issuance date.

• Confirmatory Phase 3 trial for HyBryte in CTCL to begin before year-end 2024; key data readouts for SGX945 and SGX302 expected in first half of 2025.

• Plans to secure additional capital through equity offerings, government grants, and strategic transactions, with ongoing evaluation of partnerships, M&A, and financing.